We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adverse Event Study on Anti-Tubercular Drugs.
- Authors
Rashmi, Arora; Pragya, Sharma
- Abstract
TB is an infectious disease caused by the bacillus Mycobacterium tuberculosis. It spreads from person to person primarily through the air, and it most often affects the lungs. If this disease not treated at proper time, it can be incurable. It typically affects the lungs (pulmonary TB) but can affect other sites as well (extra pulmonary TB). Tuberculosis can be cured with combinations of first line anti-tuberculosis drugs like Isoniazid, Rifampin, Pyrazinamide, Ethambutol & Streptomycin and in multi-drug resistant with second line anti TB drugs like Thiacetazone, Ethionamide, Para amino salicyclic acid, Cycloserine, Kanamycin , Amikacin and also other fluroquinolons. The TB patient on treatment is taking more than one anti-TB medicine simultaneously and regimens last from many months to two years or more. This increases the likelihood of adverse drug reaction. Most patients on treatment for drug-resistant TB experience at least one side-effect and two thirds of such patients have had at least one medicine stopped temporarily or permanently as a result of adverse drug reaction. These ADRs damage public confidence and affect patient adherence. Pharmacovigilance (PV) needs to be an integral accompaniment to treatment programs. The most common adverse drug reaction found in present study is anorexia along with nausea, vomiting and gastritis in enrolled patient's occurred during the first 2-3 weeks of treatment. A careful patient monitoring especially during first few weeks of chemotherapy helps to avoid complication caused by therapy. A rational reporting system is also the need of an hour to successfully fight up with ADRs and to increase patient compliance for the treatment.
- Subjects
DRUG side effects; ADVERSE health care events; PATIENT compliance; DRUGS; MYCOBACTERIUM tuberculosis
- Publication
Journal of Drug Delivery & Therapeutics, 2020, Vol 10, Issue 1A, p44
- ISSN
2250-1177
- Publication type
Article